TWIST BIOSCIENCE CORP
NASDAQ: TWST (Twist Bioscience Corporation)
Last update: yesterday, 3:22AM60.40
1.95 (3.34%)
| Previous Close | 58.45 |
| Open | 58.71 |
| Volume | 2,717,941 |
| Avg. Volume (3M) | 1,292,940 |
| Market Cap | 3,703,227,136 |
| Price / Sales | 9.11 |
| Price / Book | 7.95 |
| 52 Weeks Range | |
| Earnings Date | 4 May 2026 |
| Profit Margin | -54.98% |
| Operating Margin (TTM) | -44.79% |
| Diluted EPS (TTM) | -3.25 |
| Quarterly Revenue Growth (YOY) | 23.20% |
| Total Debt/Equity (MRQ) | 18.25% |
| Current Ratio (MRQ) | 4.51 |
| Operating Cash Flow (TTM) | -56.11 M |
| Levered Free Cash Flow (TTM) | -16.89 M |
| Return on Assets (TTM) | -15.04% |
| Return on Equity (TTM) | -38.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Twist Bioscience Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.0 |
| Insider Activity | -3.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | -1.00 |
|
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 1.98% |
| % Held by Institutions | 115.15% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FINN PATRICK JOHN | - | 58.85 | -2,321 | -136,591 |
| LEPROUST EMILY M. | - | 62.91 | -9,671 | -610,257 |
| STAROVASNIK MELISSA A. | - | 61.00 | -500 | -30,500 |
| Aggregate Net Quantity | -12,492 | |||
| Aggregate Net Value ($) | -777,348 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 61.42 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| STAROVASNIK MELISSA A. | Director | 27 Apr 2026 | Automatic sell (-) | 500 | 61.00 | 30,500 |
| FINN PATRICK JOHN | Officer | 23 Apr 2026 | Sell (-) | 2,321 | 58.85 | 136,591 |
| LEPROUST EMILY M. | Officer | 22 Apr 2026 | Automatic sell (-) | 8,061 | 63.20 | 509,455 |
| LEPROUST EMILY M. | Officer | 22 Apr 2026 | Option execute | 8,061 | - | - |
| LEPROUST EMILY M. | Officer | 21 Apr 2026 | Automatic sell (-) | 1,610 | 62.61 | 100,802 |
| LEPROUST EMILY M. | Officer | 21 Apr 2026 | Option execute | 1,610 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |